Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of survodutide peptide in China. Welcome to wholesale bulk high quality survodutide peptide for sale here from our factory. Good service and reasonable price are available.
Survodutide peptide, a novel dual GLP-1/glucagon receptor agonist, harbors a lesser-discussed complexity in its structural dynamics that challenges conventional peptide drug paradigms. Unlike typical GLP-1 analogs, its chimeric design-merging glucagon's helical domain with GLP-1's C-terminal tail-creates a metastable conformation prone to pH-dependent aggregation, a nuance often overshadowed by its metabolic efficacy. This instability necessitates exotic formulation excipients like non-aqueous co-solvents (e.g., DMSO traces in lyophilized powders) to prevent fibril formation during storage, a tactic borrowed from neurodegenerative disease research. Curiously, its glucagon moiety's susceptibility to proteolytic clipping by dipeptidyl peptidase-4 (DPP-4)-despite lacking the canonical cleavage site-reveals cryptic enzyme recognition motifs through molecular dynamics simulations, suggesting evolutionary conservation of degradation pathways. The peptide's unorthodox disulfide bridge network, including a strained 11-membered ring in the glucagon segment, imposes rare synthetic hurdles: spontaneous β-elimination during solid-phase synthesis mandates low-temperature coupling with pseudoproline dipeptides.
|
|
|
Survodutide Powder COA
The discovery of Survodutide peptide(BI 456906) originated from the in-depth exploration of treatment strategies for metabolic diseases, particularly for complex diseases such as obesity and metabolic dysfunction-related fatty liver disease (MASH). Its development history can be traced back to the in-depth study of the physiological functions of glucagon and glucagon-like peptide-1 (GLP-1), as well as the synergistic mechanism of their interaction in energy metabolism.
Early research foundation: The potential of dual receptor agonists
Glucagon and GLP-1 are key hormones that regulate energy balance and blood sugar homeostasis. Glucagon promotes energy expenditure by activating the glucagon receptor (GCGR), while GLP-1 inhibits appetite and improves insulin sensitivity by activating the GLP-1 receptor (GLP-1R). However, single receptor agonists have limitations in treating metabolic diseases. For instance, GLP-1R agonists (such as liraglutide, semaglutide) can effectively reduce weight and improve blood sugar levels, but their promotion of energy expenditure is limited; while GCGR agonists can increase energy expenditure, they may cause an increase in blood sugar. Therefore, dual receptor agonists that simultaneously activate both GCGR and GLP-1R are considered to potentially offer more comprehensive metabolic benefits.
The research inspiration for the development of Survodutide was partly derived from the study of the natural hormone oxyntomodulin (OXM). OXM is a weak dual receptor agonist that can simultaneously activate GCGR and GLP-1R, and has shown weight loss and metabolic improvement effects in animal experiments. However, the receptor affinity of OXM is low and its half-life is short, which limits its clinical application. Based on this, scientists began to design and synthesize more efficient and stable dual receptor agonists. Survodutide is a breakthrough achievement in this field.
Molecular Design and Optimization: Balancing Activity and Safety
The molecular design of Survodutide aims to overcome the challenges of traditional dual receptor agonists, namely, balancing the activation ratio of GCGR and GLP-1R to avoid blood sugar fluctuations. Through structural optimization, Survodutide is designed as a glucagon analogue rather than an OXM analogue, with the activation ratio of GCGR to GLP-1R being approximately 1:8 (data from in vitro experiments). This ratio design ensures that the hypoglycemic and weight loss effects mediated by GLP-1R dominate, while the activation of GCGR moderately increases energy expenditure, thereby maintaining blood sugar stability while achieving weight loss.
Furthermore, the molecular structure of Survodutide incorporates a C18 dicarboxylic group, which can bind to albumin and significantly prolong its half-life, enabling the drug to be administered via subcutaneous injection once a week. This improvement greatly enhances patient treatment compliance and provides convenience for long-term treatment.
Preclinical studies: Validation of efficacy and safety
In the preclinical studies, Survodutide demonstrated significant metabolic improvement effects. Animal experiments showed that Survodutide could reduce food intake, increase energy consumption, and effectively lower body weight and improve blood sugar control. Moreover, Survodutide also exhibited a direct protective effect on the liver, capable of reducing liver fat deposition and improving liver fibrosis, which provided a scientific basis for its application in MASH treatment.
Clinical Trials: A Breakthrough from Concept to Reality
The clinical development of Survodutide began in the early 2020s and quickly advanced to the II-stage trial phase. Its first II-stage trial was conducted on overweight or obese adults without diabetes. The results showed that after 46 weeks of treatment, patients in the 4.8 mg dose group of Survodutide had an average weight reduction of 18.7% from the baseline, and the weight loss effect was dose-dependent. In addition, Survodutide also significantly improved the metabolic indicators of patients, such as waist circumference, fasting blood glucose (FPG), and glycosylated hemoglobin (HbA1c).
In the field of MASH treatment, the results of the II phase trial of Survodutide are equally remarkable. After 48 weeks of treatment, up to 64.5% of patients with F2 and F3 stage fibrosis experienced improvement in liver fibrosis and there was no deterioration of MASH, while the placebo group only had a 25.9% improvement. Moreover, Survodutide significantly reduced the liver fat content and the non-alcoholic fatty liver disease activity score (NAS) of the patients, further verifying its potential in MASH treatment.
Regulatory Approval and Future Prospects
Based on its innovative mechanism and remarkable efficacy, Survodutide has received the Fast Track designation from the US Food and Drug Administration (FDA) and the Priority Medicines (PRIME) program support from the European Medicines Agency (EMA). Currently, Survodutide is undergoing multiple Phase III clinical trials to further evaluate its long-term efficacy and safety in obesity, MASH, and other metabolic diseases.
Selection of microbial expression systems
Survodutide peptide is a dual agonist for glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R). In the process of its development, the selection of microbial expression systems needs to comprehensively consider multiple factors such as scientific compatibility, economy, and risk control. The following analysis is conducted from three aspects: technical principle, system comparison, and practical application cases.
Technical Principle: Post-translational Modification Requirements Determine System Selection
The molecular design of Survodutide peptide integrates the core sequence of glucagon analogues with the GLP-1 receptor agonistic function, and achieves binding to albumin through the C18 dicarboxyl group modification, thereby extending the half-life to once-weekly administration. This design imposes two core requirements on the expression system:
Glycosylation modification ability: Although Survodutide itself does not rely on complex glycosylation, the post-translational modifications such as disulfide bond formation and amidation that may exist in its molecule require the endoplasmic reticulum-Golgi body processing pathway of the eukaryotic system. For example, mammalian cells (such as CHO and HEK293) can ensure the correct pairing of disulfide bonds and avoid the inclusion body problems that occur easily in the prokaryotic system.
Secretion expression efficiency: Survodutide needs to achieve the active conformational folding through the secretion pathway. Although the yeast system (such as Pichia pastoris) has secretion capabilities, its excessive glycosylation may affect the drug safety; while the glycosylation pattern of insect cells (such as Sf9) is closer to that of humans, but the cost is higher.
System Comparison: Balancing Cost, Yield and Regulatory Risks
Prokaryotic system (Escherichia coli)
Advantages: Low cultivation cost, short cycle, suitable for early activity verification. For example, the 35-amino acid core sequence of Survodutide can be rapidly expressed in Escherichia coli for structural biology research or antigen preparation.
Limitations: Unable to complete the post-translational modifications specific to eukaryotes, resulting in reduced activity; inclusion bodies require reconstitution treatment, increasing the complexity of the process. Boehringer Ingelheim may use this system to rapidly screen candidate molecules in the preclinical stage, but it is not used for final drug production.
Yeast system (Pichia pastoris)
Advantages: Combines the simplicity of prokaryotic operation with the modification ability of eukaryotes, suitable for medium-scale production. The methanol-inducible promoter of Pichia pastoris can achieve high-density fermentation, with a yield of up to kilogram per liter.
Limitations: Excessive glycosylation may cause immunogenicity, requiring gene editing (such as knocking out the glycosyltransferase gene) for optimization. If Survodutide selects this system, it needs to verify the impact of the glycosylation pattern on drug efficacy.
Mammalian system (CHO cells)
Advantages: High regulatory acceptance, accounting for 80% of the market share of biopharmaceutical production. CHO cells can stably express the full-length sequence of Survodutide, ensuring the consistency of post-translational modifications with the natural molecule. For example, through GS gene editing technology, the CHO-K1 cell line can increase the yield to 8g/L and shorten the production cycle using perfusion technology.
Limitations: High research and development cost, requiring investment in the development of stable cell lines and perfusion culture equipment. Boehringer Ingelheim is very likely to choose this system in the III clinical trial and commercialization stage to ensure process stability.
Practical Application Cases: System Evolution from Research to Commercialization
Early research stage: Boehringer Ingelheim may use the HEK293 transient transfection system to quickly verify the activity of Survodutide. This system can obtain milligram-level protein in a few weeks, meeting the requirements of pharmacodynamics research, while avoiding the long-term investment in the development of stable cell lines.
Clinical pre-development stage: To balance speed and quality, yeast stable cell lines or CHO stable cell lines become candidate solutions. For example, expressing Survodutide through methanol-inducible Pichia pastoris can complete the toxicology batch production in 2 weeks; while the CHO cell line, although requiring 3-6 months of development, can ensure process consistency.
Clinical and commercialization stage: The CHO system becomes the mainstream choice. Its advantages lie in:
Regulatory compliance: The FDA/EMA has mature guidelines for the CHO platform, reducing approval risks.
Scale-up potential: Combined with perfusion culture technology, a single batch yield can reach kilogram level, meeting global market demand.
Intellectual property layout: Boehringer Ingelheim can avoid patent disputes by choosing open-source CHO variants (such as GS-KO CHO), while using domestic culture media to reduce supply chain risks.
Future Trends: System Innovation Driven by Synthetic Biology
With the development of synthetic biology, new expression systems are breaking through the traditional limitations:
Human cell line (PER.C6)
Can reduce immunogenicity, but additional verification of virus safety is required.
Cell-free expression system
Suitable for the rapid production of toxic proteins (such as anti-cancer drugs), but cost and scalability remain bottlenecks.
Continuous production technology
The CHO cell perfusion process can increase production capacity by 3-5 times, becoming the core direction for future commercial production.
Conclusion
he microbial expression system for Survodutide peptide exhibits "stage-specific" characteristics: in the early stage, rapid validation of activity is achieved through transient transfection in HEK293 cells. During the preclinical development phase, the cost-effectiveness of Pichia pastoris and CHO systems is weighed. Finally, in the commercialization stage, a stable CHO cell line is selected to balance yield, quality, and compliance. This strategy embodies the core logic of "scientific adaptability priority, economic drive, and risk control" in the field of biopharmaceuticals, providing a paradigm reference for the development of similar dual receptor agonists.
Hot Tags: survodutide peptide, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, Cosmetic, DERMORPHIN, dermorphin in humans, dermorphin peptide, Melanotan ii powder